Revvity, Inc. (RVTY)
NYSE: RVTY · Real-Time Price · USD
96.95
+1.57 (1.65%)
May 22, 2026, 4:00 PM EDT - Market closed

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Jan '17 Jan '16 Dec '14
Total Diagnostics Revenue (Pre-Q3 2022)
1.45B1.42B1.36B
Total Diagnostics Revenue (Pre-Q3 2022) Growth
1.75%5.05%4.96%
Revenue (Other)
1.45B1.43B1.40B
Revenue (Total)
2.90B2.86B2.76B
Revenue (Total) Growth
1.62%3.67%0.16%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Jan '17 Jan '16 Dec '14
Life Sciences Revenue (Post-Q2 2022)
1.45B1.43B1.40B
Life Sciences Revenue (Post-Q2 2022) Growth
1.50%2.32%-4.09%
Total Diagnostics Revenue (Pre-Q3 2022)
1.45B1.42B1.36B
Total Diagnostics Revenue (Pre-Q3 2022) Growth
1.75%5.05%4.96%
Revenue (Total)
2.90B2.86B2.76B
Revenue (Total) Growth
1.62%3.67%0.16%

Revenue Breakdown 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Jan '17 Jan '16 Dec '14
Total Diagnostics Revenue (Pre-Q3 2022)
1.45B1.42B1.36B
Total Diagnostics Revenue (Pre-Q3 2022) Growth
1.75%5.05%4.96%
Total Product Revenue
2.41B2.39B2.34B
Total Product Revenue Growth
0.94%2.21%-3.21%
Total Service Revenue
490.02M466.07M416.82M
Total Service Revenue Growth
5.14%11.82%24.54%
Revenue (Total)
2.90B2.86B2.76B
Revenue (Total) Growth
1.62%3.67%0.16%

EBIT 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Jan '17 Jan '16 Dec '14
Life Sciences Operating Income (Post-Q2 2022)
456.53M458.26M467.28M
Life Sciences Operating Income (Post-Q2 2022) Growth
-0.38%-1.93%-8.78%
Diagnostics Operating Income (Pre-Q3 2022)
346.27M344.17M353.94M
Diagnostics Operating Income (Pre-Q3 2022) Growth
0.61%-2.76%18.76%
Operating Income (Total)
360.29M356.64M346.74M
Operating Income (Total) Growth
1.03%2.85%15.36%

EBIT 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22 Jan '21 Dec '19 Dec '18 Dec '17 Jan '17 Jan '16 Dec '14
Diagnostics Operating Income (Pre-Q3 2022)
346.27M344.17M353.94M
Diagnostics Operating Income (Pre-Q3 2022) Growth
0.61%-2.76%18.76%
Operating Income (Total)
360.29M356.64M346.74M
Operating Income (Total) Growth
1.03%2.85%15.36%
Updated May 12, 2026. Data Source: Fiscal.ai.